Abstracts tagged "opportunistic infections and rheumatoid arthritis (RA)"

Abstract Number: 1227 • 2018 ACR/ARHP Annual Meeting
Indicator Opportunistic Infections after Biological Treatment in Rheumatoid Arthritis, 10 Years Follow up in Clinical Practice
Leticia Leon^1,2, Marina Peñuelas³, Francisco Javier Candel³, Dalifer Freites Núñez⁴, Luis Rodriguez-Rodriguez⁵, Zulema Rosales Rosado⁶ and Lydia A Alcazar⁷, ¹Rheumatology Department, Hospital Clínical San Carlos, and IdISSC, Madrid, Spain, ²Health Sciences, Universidad Camilo Jose Cela, Madrid, Spain, ³Microbiology, Microbiology Department. Hospital Clínico San Carlos, Madrid, Spain., Madrid, Spain, ⁴Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ⁵Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ⁶Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ⁷Rheumatology Department and Heath Research Institute (IdISSC), Hospital Clinico San Carlos, Madrid, Spain
Background/Purpose: Biologic disease-modifying anti-rheumatic drugs (bDMARDs) may be associated with opportunistic infections. Our purposes were to describe their incidence in Rheumatoid Arthritis (RA) taking bDMARDs,…
Abstract Number: 2410 • 2017 ACR/ARHP Annual Meeting
Serious Infection Risk in Patients with Rheumatoid Arthritis Compared to Patients with Non-Inflammatory Rheumatic Diseases: A US National Cohort Study
Bella Y. Mehta¹, Sofia Pedro², Gulsen Ozen³ and Kaleb Michaud⁴, ¹Rheumatology, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ²National Data Bank for Rheumatic Diseases, Wichita, KS, ³Rheumatology, Marmara University, School of Medicine, Rheumatology, Istanbul, Turkey, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Serious infections (SI) in patients with rheumatoid arthritis (RA) are a perpetual concern. We compared the risk by first and recurrent SIs in patients…
Abstract Number: 482 • 2014 ACR/ARHP Annual Meeting
Incidence of Opportunistic Infections in Rheumatoid Arthritis Treated with Biological Agents
Alejandro Gomez-Gomez^1,2, Zulema Rosales^1,2, Leticia Leon², Juan A Jover², Luis Rodriguez-Rodriguez² and Lydia Abasolo², ¹Rheumatology, Hospital Clinico San Carlos, Madrid, Spain, ²Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain
Background/Purpose With the expanding use of Biological Agents (BA), in particular TNF inhibitors, opportunistic infections (OI) are a major concern in Rheumatology. Our purposes were…
Abstract Number: 2093 • 2012 ACR/ARHP Annual Meeting
Rates of Opportunistic Infections Among Rheumatoid Arthritis Patients Switching Biologic Therapy
John Baddley¹, Shuo Yang², Klye Brizendine³, Scott DuVall⁴, Kevin L. Winthrop⁵, Mary J. Burton⁶, Nivedita M. Patkar⁷, Elizabeth S. Delzell⁸, Monika M. Safford⁹, Jasvinder A. Singh¹⁰, Iris E. Navarro¹¹, Grant W. Cannon¹², Ted R. Mikuls¹³, Lang Chen¹¹, Kenneth G. Saag¹⁴, Kimberly Alexander¹⁵, Pavel Napalkov¹⁵, Aaron Kamauu¹⁶ and Jeffrey R. Curtis¹⁷, ¹Medicine, University of Alabama at Birmingham, Birmingham, AL, ²Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Infectious Disease, Birmingham, AL, ⁴VA Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, ⁵Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ⁶VA Hospital, Jackson, MS, ⁷Immunology/Rheumatology, Univ of Alabama-Birmingham, Birmingham, AL, ⁸Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁹Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, ¹⁰Department of Medicine, University of Alabama, Tuscaloosa, AL, ¹¹Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹²Division of Rheumatology, George E. Wahlen VA Medical Center, Salt Lake City, UT, ¹³Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ¹⁴Div Clinical Immun & Rheum, Univ of Alabama-Birmingham, Birmingham, AL, ¹⁵Epidemiology, Genentech, Inc., South San Francisco, CA, ¹⁶Anolinx, Bountiful, UT, ¹⁷Rheumatology & Immunology, Univ of Alabama-Birmingham, Birmingham, AL
Background/Purpose: The incidence of opportunistic infections (OIs) in patients on biologics is low, but may approach several cases per 100 person-years (PY). Data on risks…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].